Although the frequency of IDH mutation in primary glioblastoma is low (~ 8%)1,2, noninvasive imaging-based determination of IDH mutation status can predict response to anti-IDH treatment or vaccination3–6. The gene discussed is IDH2; the disease is glioblastoma.